Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of NGM621 in Geographic Atrophy
NCT04014777Phase 1Completed
- Sponsor
- NGM Biopharmaceuticals
- Start
- Jul 2019
- Primary completion
- May 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ngm621 in geographic atrophy (GA) (4 arms), sponsored by NGM Biopharmaceuticals. Primary endpoint: Incidence and Severity of Ocular and Systemic Treatment-Emergent Adverse Events at 12 weeks. Started Jul 2019; status: completed.
02
Drugs
ngm621
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT04014777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04014777.